Compositions comprising desoximetasone and tazarotene
OwnerXiaopin JIN, Bean NEZIR +4inventors
InventorsXiaopin JIN, Bean NEZIR, Brenden HADJIKEZIAN, Shen GAO, Ron SCHLINGER, Avi AVRAMOFF
Life of this patent
Estimating the term…
Abstract
The present disclosure provides formulations comprising desoximetasone, tazarotene, a polymer comprising polyurethane, and a solvent. Also provided herein are methods of co-administering desoximetasone and tazarotene.
Claims38
A topical pharmaceutical formulation comprising:
- a. about 0.01% wt/wt to about 1% wt/wt desoximetasone;
- b. about 0.01% wt/wt to about 1% wt/wt tazarotene;
- c. a polymer comprising polyurethane;
- and
- d. a solvent.
The formulation of any one of claims 1 to 23, wherein the desoximetasone and the tazarotene are both soluble in the solvent.
A topical pharmaceutical formulation comprising:
- a. about 0.03% wt/wt to about 0.15% wt/wt desoximetasone;
- b. about 0.05% wt/wt to about 0.1% wt/wt tazarotene;
- c. about 0.02% wt/wt to about 5% wt/wt polymer comprising C6-C14 isocyanate and polypropylene glycol;
- and
- d. about 0.2% wt/wt to about 10% wt/wt organic, polyol solvent.
A method of co-administering desoximetasone and tazarotene, the method comprising topically administering a formulation comprising desoximetasone;
- tazarotene;
- a polymer comprising polyurethane;
- and a solvent, wherein the desoximetasone skin permeation through the skin is inhibited at least 20% compared to a formulation not comprising the polymer.
A method of co-administering desoximetasone and tazarotene, the method comprising topically administering a formulation comprising desoximetasone;
- tazarotene;
- a polymer comprising polyurethane;
- and a solvent, wherein the hypothalamic pituitary adrenal (HPA) axis suppression is reduced at least 10% compared to a formulation not comprising the polymer.
Dependencies are inferred from the claim text.